Tilray CEO: Opportunities in clinical cannabis are substantial

Tilray CEO: Opportunities in clinical cannabis are substantial

Tilray’s stock is up this present day, but soundless down 80 p.c from a February high. CNBC’s Frank Holland experiences on his dialog with Tilray CEO Irwin Simon about the…